Precision Diabetes and DirectSens Partner to Launch MetMark™ AHB Test in the U.S.
Why now
Thesis: Early-detection biomarker could reshape diabetes screening
Catalyst to watch: Clinical adoption or payer reimbursement decisions
Main risk: Unproven reimbursement and slow clinical uptake
Why it matters
A new diabetes risk test could shift screening earlier, but commercial adoption and reimbursement are unproven.
Details
New research shows alpha-hydroxybutyrate can identify increased type 2 diabetes risk nearly a decade before diagnosis; DirectSens technology enables routine clinical chemistry testing RALEIGH, N.C. and VIENNA, Sept. 23, 2026 /PRNewswire/ -- Precision Diabetes, Inc. (PDI) and DirectSens...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-23 11:00 UTC